Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy by Lam, Edwin et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Pharmacology and Experimental 
Therapeutics Faculty Papers 
Department of Pharmacology and Experimental 
Therapeutics 
6-26-2019 
Drug interactions between direct-acting oral anticoagulants and 
calcineurin inhibitors during solid organ transplantation: 
considerations for therapy 
Edwin Lam 
Thomas Jefferson University 
Babar Bashir 
Thomas Jefferson University 
Mark Chaballa 
Thomas Jefferson University 
Walter K. Kraft 
Thomas Jefferson University 
Follow this and additional works at: https://jdc.jefferson.edu/petfp 
 Part of the Medical Pharmacology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Lam, Edwin; Bashir, Babar; Chaballa, Mark; and Kraft, Walter K., "Drug interactions between 
direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: 
considerations for therapy" (2019). Department of Pharmacology and Experimental 
Therapeutics Faculty Papers. Paper 108. 
https://jdc.jefferson.edu/petfp/108 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an 
authorized administrator of the Jefferson Digital Commons. For more information, please contact: 
JeffersonDigitalCommons@jefferson.edu. 
1 
 
Review Article Title: 1 
Drug Interactions between Direct-Acting Oral Anticoagulants and Calcineurin Inhibitors during Solid 2 
Organ Transplantation: Considerations for Therapy  3 
 4 
Authors & Affiliations: 5 
Edwin Lam, PharmD1, Babar Bashir, MD, MS2, Mark Chaballa, PharmD3, and Walter K. Kraft, MD1 6 
 7 
1Department of Pharmacology & Experimental Therapeutics, Thomas Jefferson University, Philadelphia, 8 
PA, USA 9 
2Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA 10 
3Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA, USA  11 
 12 
Corresponding author: 13 
Edwin Lam, PharmD; edwin.lam@jefferson.edu 14 
Department of Pharmacology & Experimental Therapeutics 15 
Thomas Jefferson University 16 
1170 Main Bldg; 132 S. 10th Street 17 
Philadelphia, PA 19107-5244 18 
Tel: (215) 955-5916 19 
Fax: (215) 955-5681 20 
 21 
Running Head (short title): 22 
DOAC and CNI PK/PD Interaction 23 
 24 
Manuscript metrics: 25 
Title (with spaces)   150 26 
Running title (with spaces)  30 27 
Abstract (words)   190 28 
Body of manuscript (words)  4983 29 
References    77 30 
Number of tables   1 31 
Number of figures   2 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
2 
 
Abstract 42 
Introduction: There is a high incidence of venous thromboembolism (VTE) in solid organ transplant 43 
recipients. The safety and efficacy of direct-acting oral anticoagulants (DOAC) have been well established 44 
in clinical practice for the prevention and treatment of VTE in broad populations. However, the 45 
management of VTE in the setting of solid organ transplantation remains a challenge to clinicians due to 46 
limited evidence of DOAC usage with calcineurin inhibitors.  47 
 48 
Areas covered: The current literature available on the pharmacokinetic-pharmacodynamic interaction 49 
between DOACs and calcineurin inhibitors is presented. A comprehensive review was undertaken using 50 
PubMed, Embase, drug product labeling, and drug product review conducted by the US Food and Drug 51 
Administration using Drugs@FDA. The potential for mitigation strategies and clinical management using 52 
extant knowledge is explored.  53 
 54 
Expert Opinion: Immunosuppression therapy is necessary to prevent graft rejection by the host. The 55 
sparsity of data together with the lack of well-designed prospective studies of DOAC use in solid organ 56 
transplant recipients presents a unique challenge to clinicians in determining the clinical relevance of 57 
possible drug interactions. Existing evidence suggests that with attention to concomitant drug use and 58 
renal function, the co-administration of DOACs and calcineurin inhibitors is safe and effective. 59 
 60 
Keywords: direct oral anticoagulants, DOAC, cyclosporine, tacrolimus, anticoagulation, venous 61 
thromboembolism, apixaban, rivaroxaban, dabigatran, warfarin 62 
Funding details: Edwin Lam is supported by a National Institutes of Health training grant T32GM008562.  63 
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Article Highlights 64 
• The calcineurin inhibitors, cyclosporine and tacrolimus, are commonly used in maintenance 65 
immunosuppression regimens to prevent graft rejection following solid organ transplant. 66 
Cyclosporine may have a higher likelihood of inhibiting drug metabolizing enzymes and transporters 67 
compared to tacrolimus.  68 
• Direct oral anticoagulant (DOAC) clinical trials often excluded those on either cyclosporine or 69 
tacrolimus.  70 
• Identifying intrinsic and extrinsic variabilities in the pharmacokinetics-pharmacodynamics in solid 71 
organ transplant recipients may balance the risks of bleeding while maintaining adequate 72 
anticoagulation.  73 
• The Cockcroft-Gault formula using ideal body weight is used for dosing adjustments for apixaban and 74 
edoxaban while actual body weight is used to adjust dabigatran and rivaroxaban. 75 
• While limited, pharmacokinetic-pharmacodynamic and outcomes evidence suggests safe and 76 
effective use of DOACs together with calcineurin inhibitors. 77 
• Anti-Factor Xa monitoring is not standardized and is not helpful in dose selection. 78 
• Direct oral anticoagulant use should be avoided in the immediate post-operative period and 79 
considered only after there is stability of renal and hepatic function and when bleeding risk has 80 
stabilized. 81 
• Dose adjustment should not be made in the setting of acute thrombosis. After at least three months 82 
of therapy, intrinsic and extrinsic factors may inform the use of switching to attenuated dose for 83 
secondary thromboprophylaxis 84 
 85 
 86 
 87 
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1. Introduction 88 
Solid organ transplantation offers a lifesaving option to patients with end-stage kidney, liver, 89 
heart, or lung disease. Between 1987 and 2012, 2 million life-years were saved by solid organ 90 
transplantation in the United States.[1] Acute and chronic immunosuppression therapy has been 91 
established as the cornerstone to prevent graft rejection, subsequent loss of the transplanted organ, and 92 
overall survival of the patient. Management of the transplant recipient using immunosuppression therapy 93 
is multi-modal where most immunosuppressive regimens include the calcineurin inhibitors (CNI) 94 
cyclosporine (CsA) and tacrolimus.[2-4] 95 
Following solid organ transplantation, the incidence for venous thromboembolism (VTE) was 5%, 96 
14%, 29%, and 34%, for patients that underwent liver, renal, lung and heart transplant, respectively.[5] 97 
Although the reasons for higher incidence is not defined, factors including thrombophilic states (e.g. 98 
protein C, S or antithrombin III deficiency), clinical (e.g. diabetes mellitus, systemic lupus erythematosus), 99 
or donor-recipient (e.g. donor/recipient atheroma) have been proposed.[6] A thrombogenic state induced 100 
by immunosuppressive therapy has also been proposed based on in-vitro and clinical observations, 101 
however studies in renal transplant recipients remain contradictory.[7,8] Aside from the thrombogenic 102 
risk following organ transplant, risks for VTE are also inherent in patients who are greater than 40 years-103 
old, immobile, or obese.[9] 104 
The vitamin K antagonist warfarin has been the historical standard of care for the oral treatment 105 
of VTE. In solid organ transplant recipients, most protocols involve administering a parenteral 106 
anticoagulant (heparin or low molecular weight heparin) followed by warfarin maintenance for 3-6 107 
months.[5] In the general patient population, the direct acting oral anticoagulants (DOAC) are at least as 108 
efficacious as warfarin. They have fewer drug interactions, a wider therapeutic window, and a fixed-dose 109 
regimen without continuous monitoring of the coagulation profile. While these characteristics are 110 
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particularly appealing for use in clinical care, specific guidance in transplant patients is lacking since this 111 
population has been excluded from clinical trials of DOACs.  112 
Calcineurin inhibitors block several drug transporters and metabolizing enzymes. Direct oral 113 
anticoagulants are substrates of specific drug transporters and metabolic enzymes involved in the 114 
absorption and elimination of drugs. Given the incidence of VTE following solid organ transplant and the 115 
prevalent use of CNIs in maintenance immunosuppressive regimens, the use of DOACs together with CNIs 116 
may result in a drug-drug interaction (DDI). These drug interactions are most impactful at treatment doses 117 
for labeled indications of venous thromboembolic disease or atrial fibrillation, rather than the lower doses 118 
used for primary prevention of venous thromboembolic disease. 119 
 120 
2. Maintenance Pharmacotherapy in the Solid Organ Transplant Recipients: Calcineurin Inhibitors 121 
2.1. Tacrolimus 122 
Tacrolimus is a macrolide antibiotic isolated from Streptomyces tsukubaensis. Its mechanism 123 
involves complexation with the immunophilin FK-binding protein which produces immunosuppression by 124 
downstream inhibition of cytokine production and a loss of T-lymphocyte activation, proliferation, and 125 
response. Tacrolimus is part of maintenance immunosuppression in over 80% of kidney, pancreas, liver, 126 
intestine, heart, and lung transplant recipients and is indicated for the prophylaxis of organ rejection in 127 
kidney, liver and heart transplant.[10,11] Following oral administration, tacrolimus is extensively 128 
metabolized by cytochrome P450 (CYP) CYP3A4 and CYP3A5 and is a substrate for permeability 129 
glycoprotein (P-gp). It is unclear whether tacrolimus has the potential to inhibit drug metabolizing 130 
enzymes or efflux transporters in humans. While in-vitro and non-human in-vivo models have described 131 
a possible inhibitory effect on CYP3A4 and P-gp,[12] the pharmacokinetic impact of tacrolimus and other 132 
CYP3A and P-gp substrates in healthy volunteers is likely to be clinically irrelevant in patient 133 
populations.[13,14]  134 
 135 
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2.2. Cyclosporine 136 
Isolated from the fungal species Tolypocladiumin flatum found in soil, cyclosporine was originally 137 
developed as an antifungal medication. Reduction in T-lymphocyte activity and immunosuppression by 138 
CsA occurs through the binding and complex formation with cyclophilin that results in downstream 139 
transcriptional inactivation of various interleukins and cytokines. Cyclosporine is extensively metabolized 140 
by CYP3A4 in the intestine and liver and is a P-gp substrate.[15] In addition, CsA is a potent inhibitor of 141 
intestinal and hepatic efflux transporters including breast cancer resistance protein (BCRP) and P-gp; 142 
hepatic uptake transporters such as organic anion transporting polypeptide (OATP); and CYP3A4. Drug 143 
metabolism by 3A4 takes place in liver and pre-systemically in the intestine. Due to its activity at the level 144 
of the intestines and liver, CsA may pose clinically relevant DDIs as both the victim and perpetrator drug. 145 
Cyclosporine is indicated for the prophylaxis of organ transplant rejection following kidney, liver, and 146 
heart transplantation.[16,17] Although tacrolimus appears to be the favored CNI in the US and Asia, there 147 
is still considerable global use of CsA.[18,19] Dose-dependent acute nephrotoxicity and chronic 148 
nephropathy from CsA exposure is a significant adverse event contributing to renal dysfunction following 149 
renal or non-renal transplant.  150 
 151 
3. Pharmacokinetics Following Transplantation: Absorption, Distribution, Metabolism, & Elimination  152 
A number of physiological changes occur after transplantation which impact drug disposition 153 
(figure 1). The major transplanted organs have a direct or indirect role in drug absorption, distribution 154 
and elimination. These changes are dynamic and can occur immediately following transplantation. 155 
Changes in gastric pH and emptying, gastrointestinal motility, incidence of diarrhea, bile dysfunction, and 156 
differential expression of drug efflux transporters following transplantation can alter absorption of drugs 157 
into the systemic circulation.[20-26] Drug distribution into tissues or free-fraction availabilities have also 158 
been shown to be impaired due to fluctuations in body weight or alterations in protein binding.[27-34] 159 
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Lastly, drug elimination may be altered due to higher hepatic blood flow, upregulation of drug 160 
metabolizing enzymes, changes in bile flow, or decline in renal function.[35-40] 161 
 162 
4. Intrinsic and Extrinsic Factors Affecting DOAC Disposition in Solid Organ Transplant Recipients  163 
No formal studies have investigated the PK of DOAC therapy in solid organ transplant recipients. 164 
Variability derived from intrinsic (altered protein binding, obesity, gastric motility) and extrinsic (DDI) 165 
factors following transplantation may contribute to significant inter-recipient variability in the exposure 166 
and the efficacy or safety response to DOACs. For the purposes of this review, extrinsic factors- mainly 167 
those contributed from DDIs- will be discussed in detail.  Drug metabolizing enzymes and transporters 168 
play an important role in the disposition of drugs. The drug transporters, P-gp and BCRP, are commonly 169 
expressed in the intestinal epithelia where their expression limits entry of therapeutic drugs.[41] In 170 
excretory organs, drug transporters function to remove endogenous and xenobiotic compounds. 171 
Therefore, efflux mechanisms can result in pharmacokinetic DDIs between CNI and DOACs during the 172 
absorption or elimination phases. For CsA an interaction in the intestine can be considerable, since a large 173 
magnitude of the delivered dose is in unbound form compared to delivery to the liver. In the intestines, 174 
the inhibition of P-gp and BCRP by CsA was estimated using physiologically based pharmacokinetic 175 
modeling to be up to 80% and 67%, respectively.[42] Moreover, up to 97% of intestinal CYP3A4 is inhibited 176 
following a single oral dose. [42] In the intestines, P-gp, BCRP and CYP3A4 activity returns to maximal 177 
activity within 4-6 hours after discontinuing CsA. Within the liver, P-gp, BCRP, and CYP3A4 enzyme activity 178 
is estimated to be reduced by 4%, 2%, and 26%, respectively.[42] Tacrolimus has been shown to share 179 
common inhibitory mechanisms as CsA with significantly less inhibition potential. For stabilized renal 180 
transplant patients receiving tacrolimus, intestinal and hepatic CYP3A4 and P-gp activities are 181 
insignificant. In contrast, the activity of intestinal CYP3A4 were starkly elevated in patients on CsA together 182 
with significant reductions in intestinal and hepatic P-gp.[43] These findings enforce the differential 183 
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effects of CsA and tacrolimus on drug metabolizing enzymes and transporters for which a greater variation 184 
in drug exposure is anticipated for drugs co-administered with CsA. Clinically, the magnitude of tacrolimus 185 
inhibition on CYP3A4 and P-gp is expected to be minimal at therapeutic drug doses. [12,43]  186 
It is important to keep in mind that although the magnitude of inhibition of transporters and 187 
enzyme may appear large, differential expression along the length of the small intestine and lower 188 
abundance of protein relative to the liver may minimize drug interaction potential.[44] In the case of the 189 
DOACs, clinically relevant DDIs may result at the level of absorption (i.e. the intestines) or elimination (i.e. 190 
renal or non-renal routes) when given together with CsA or tacrolimus. All DOACs are substrates of drug 191 
efflux transporters and, with the exception of dabigatran, substrates for CYP3A4. Use of P-gp or CYP3A4 192 
inhibitors, especially CsA or tacrolimus, were mostly excluded from pivotal trials in patients during the 193 
clinical development of each DOAC.[45-48] While information related to the clinical relevance of the DDI 194 
in patient populations is limited, available PK studies in healthy volunteers may provide insight in the 195 
magnitude of change and its relationship to safety and efficacy. Table 1 summarizes the extrinsic factors 196 
relating to DDIs for DOACs and their respective exposure and peak concentration changes in the presence 197 
of their substrate transporter and/or enzyme inhibitor. In the absence of a dedicated CsA or tacrolimus 198 
study, we reference available substrate transporter and/or enzyme inhibitors that share the same 199 
mechanistic pathways to provide insight to the magnitude of changes in the exposure and peak 200 
concentrations.  201 
4.1. Dabigatran 202 
Dabigatran etexilate directly and reversibly inhibits thrombin, rather than reducing the 203 
production of vitamin K dependent clotting factors.[49] Dabigatran etexilate is a prodrug that is orally 204 
absorbed with an absolute bioavailability of approximately 3-7%. Conversion to the active moiety, 205 
dabigatran, is independent of CYP isoenzymes and is formed following hydrolysis by carboxylesterases. It 206 
is the prodrug that is a substrate of P-gp rather than the active moiety, which may account for its low 207 
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bioavailability and variable PK. In addition, changes in gastric pH and intestinal motility have also 208 
contributed to the observed differences in PK following surgery.[50] The volume of distribution is 209 
moderate at 60 liters with an in-vitro plasma protein binding of 35% across therapeutic concentrations. 210 
Dabigatran, but not dabigatran etexilate, is detectable in systemic circulation following oral 211 
administration. Dabigatran metabolism is minimal and it is not a substrate or inhibitor of CYP450 enzymes. 212 
Renal clearance is the major route of dabigatran drug elimination representing 80% of the total clearance. 213 
Following intravenous dosing, greater than 80% of the dose was recovered in the urine compared to only 214 
7% after oral administration. The remaining 86% of orally dosed dabigatran was recovered in the feces 215 
most likely due to incomplete absorption of DE. Dabigatran elimination half-life is 12-17 hours.  216 
Dabigatran etexilate exhibits predominately P-gp dependent transport, demonstrated by in-vitro 217 
inhibition studies using verapamil as a P-gp inhibitor.[51] In the presence of CsA, a P-gp and BCRP inhibitor, 218 
greater than 80% of efflux was inhibited as observed using the same in-vitro Caco-2 permeability model. 219 
These results implicate CsA as a potential perpetrator for clinical in-vivo drug interactions following co-220 
administration with dabigatran etexilate. To date, no dedicated in-vivo clinical studies have been 221 
conducted evaluating the DDI between dabigatran etexilate co-administered with either CsA or 222 
tacrolimus. P-gp inhibition may be time-dependent and influenced by the timing of a co-administered 223 
perpetrator. Following multiple oral doses of verapamil in healthy volunteers, total dabigatran exposure 224 
and peak concentration increased by 54% and 63% after a single-oral 150 mg dabigatran etexilate dose 1 225 
hour after verapamil, respectively.[52] When dabigatran etexilate was given 2 hours prior to verapamil, 226 
exposure and peak concentration increased by 18% and 12%, respectively. Considering the inhibition 227 
activity of CsA in-vitro, results from co-administered verapamil alone may not satisfy the clinical relevance 228 
of both P-gp and BCRP inhibition. Insightful results based on in-silico modeling using ritonavir, a dual P-gp 229 
and BCRP inhibitor, have estimated exposure and peak concentration increases of approximately 25% and 230 
16%, using a simulated 200 mg twice-daily regimen, respectively.[53]  231 
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Dabigatran transporter mediated DDIs are best assessed using data obtained in healthy 232 
volunteers using the broad ATP-binding transporter and CYP3A4 inhibitor ritonavir.[54] Following 233 
multiple-oral doses of ritonavir 100 mg daily, single-dose dabigatran exposure was increased by 15% when 234 
administered simultaneously and reduced by 29% when dabigatran etexilate was administered 2 hours 235 
prior to dosing ritonavir. These observations likely confirm the time-dependency of co-administered 236 
perpetrator drugs on the PK profile of dabigatran. P-gp inhibition and renal dysfunction are both 237 
independent factors that enhances the exposure of DE.  238 
In patients receiving dabigatran etexilate for treatment and prevention of VTE, there is no dosage 239 
adjustment or contraindication to P-gp inhibitors so long as patients have a creatinine clearance greater 240 
than 50 mL/min.[55] These recommendations are intuitive considering the most important factor 241 
influencing dabigatran exposure is renal clearance. Therefore, the use of dabigatran etexilate is 242 
completely contraindicated in those with creatinine clearances less than 50 mL/min. Despite these results, 243 
the U.S. labelling for CsA suggests avoiding co-administration with dabigatran etexilate altogether 244 
regardless of renal function.[16,17] Drug-drug interactions involving dabigatran etexilate may be 245 
restricted to only intestinal P-gp rather than other sites. In addition, BCRP and CYP3A4 liability is not a 246 
general concern as witnessed from in-vitro permeability models and clinical DDI studies using the P-gp, 247 
BCRP and CYP3A4 inhibitor, ritonavir. Based on these findings, dabigatran is a suitable choice in transplant 248 
patients co-prescribed CsA or tacrolimus, so long as estimated creatinine clearance is > 50 ml/min. As the 249 
risk of higher exposures and subsequent bleeding risk will be low in those with creatinine clearances 250 
greater than 50 mL/min using a CNI, caution should be enforced especially during periods of fluctuating 251 
physiology during the post-transplant period. A shorter acting parenteral anticoagulant should be 252 
considered before dabigatran until renal function stabilizes and the bleeding risk has declined. In the 253 
setting of acute VTE, the label outlines at least five days of treatment be with a parenteral agent (heparin 254 
or enoxaparin) before transitioning to dabigatran etexilate.  255 
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4.3. Rivaroxaban 256 
Rivaroxaban is a direct oral factor Xa (FXa) inhibitor approved by the FDA for the treatment and 257 
prevention of recurrent VTE and reducing risk of stroke in atrial fibrillation.[56] Absolute bioavailability is 258 
dose dependent where almost complete absorption (80 to 100%) is achieved at the 10 mg dose but 259 
reduced to 66% for the 20 mg dose. The site of absorption is primarily in the proximal small intestine 260 
where peak concentrations are observed 2 to 4 hours following oral intake. Rivaroxaban is highly bound 261 
to plasma proteins with a steady-state volume of distribution of 50 liters.  Approximately two-thirds of 262 
the administered dose is subjected to metabolic transformation through CYP3A4/5 and CYP2J2 263 
metabolism where it accounts for 18% and 14% of the total rivaroxaban elimination, respectively. No 264 
major active circulating metabolites in plasma are present following administration. The remaining one-265 
third of the administered dose is eliminated renally as unchanged drug where 30% is removed through 266 
active renal secretion and the remaining 6% through glomerular filtration. The elimination half-life in 267 
healthy subjects is 5 to 9 hours whereas elderly subjects had prolonged half-lives ranging from 11 to 13 268 
hours. Rivaroxaban is a substrate for the efflux transporters P-gp and BCRP and has equal affinity for both 269 
transporters.[51] 270 
Based on pooled phase I results, the impact of age, race, renal and hepatic insufficiency were 271 
observed to influence the area under the concentration-time curve (AUC). Healthy elderly subjects older 272 
than 75 years of age have greater than 40% higher exposures, primarily due to a decline in renal function 273 
and non-renal rivaroxaban clearance.[57]. A dose-reduction strategy is recommended to account for renal 274 
function based on creatinine clearance.[56]  275 
Although there is no dedicated DDI study with CsA, similar perpetrator inhibitors- such as 276 
erythromycin- sharing the same inhibitory pathway may offer an insight in the magnitude of 277 
interaction.[58] Erythromycin is a combined P-gp and moderate CYP3A4 inhibitor which shares the same 278 
characteristic as CsA. Following multiple-doses of erythromycin, the AUC and peak concentrations are 279 
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increased by 34% and 38% after a single-dose of rivaroxaban. Similarly, the AUC and Cmax are increased 280 
by 42% and 28% following co-administration with the combined moderate CYP3A4 and BCRP inhibitor 281 
fluconazole. These individual elevations in the AUC and peak concentrations alone do not warrant a 282 
dosage change or contraindication as these values fall within the ranges observed of drug use in the 283 
general patient population. Although one intrinsic or extrinsic factor alone does not preclude the use of 284 
rivaroxaban, the presence of greater than one factor may present a complex drug-drug and drug-disease 285 
interaction producing a clinically significant increase in rivaroxaban exposure. When accounting for renal 286 
function, age, and DDI with erythromycin, increase in the AUC by 1.9, 2.4, and 2.6-fold were predicted in 287 
younger patients with mild, moderate, or severe renal impairment while co-administered erythromycin, 288 
respectively.[59] The impact from older age with erythromycin (55-65 years old) predicted a 2.5, 2.9 and 289 
3-fold increase in the AUC in individuals with mild, moderate or severe renal impairment, respectively. 290 
Although these results should not be extrapolated to those using CsA or tacrolimus, cautious monitoring 291 
and careful clinical consideration for rivaroxaban use should be practiced especially in older patients with 292 
reduced renal function.  293 
4.4. Edoxaban 294 
Edoxaban is a selective inhibitor of FXa indicated for the risk reduction of stroke and emboli in 295 
non-valvular atrial fibrillation and treatment of VTE.[60] Like dabigatran but unlike the other FXa 296 
inhibitors, edoxaban is labeled to be started after 5 to 10 days of parenteral anticoagulation in the 297 
treatment of acute VTE. Edoxaban demonstrates pH-dependent solubility where optimal dissolution is 298 
achieved in the pH range of 3 to 5. Absorption primarily occurs in the proximal small intestine with an 299 
absolute bioavailability of 62%. The volume of distribution is estimated to be 107 liters and plasma protein 300 
binding is estimated to be about 55% for concentrations from 0.2 to 5 ug/mL. Edoxaban metabolism is 301 
primarily mediated by carboxylesterase 1 (CES1) and CYP3A4. M4, an active circulating metabolite in 302 
plasma, is formed following CES1 metabolism and contributes to 10% of the total edoxaban systemic AUC. 303 
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Approximately 50% of the total clearance of unchanged edoxaban is through the kidneys with the 304 
remaining half appearing in feces and bile. After oral administration, the terminal elimination half-life is 305 
10 to 14 hours. Edoxaban is a substrate for P-gp with its active metabolite, M4, a substrate for the influx 306 
transporter OATP1B1. In-vitro evidence suggests equivalent efflux transport from P-gp and BCRP.[51] 307 
In the registration trial for use in VTE, study patients on concurrent P-gp inhibitors with body 308 
weight < 60 kg or moderate renal impairment received an edoxaban dose reduction to 30 mg daily with 309 
patients on CsA excluded from the study.[47] Edoxaban prolongs the prothrombin time in a 310 
concentration-dependent manner with a linear relationship between edoxaban and anti-FXa. The AUC of 311 
drug concentration is a predictor of therapeutic response when compared to warfarin across subjects with 312 
normal, mild, or moderate renal function.[61]  313 
 The interaction between edoxaban and CsA has been evaluated in healthy volunteers. Co-314 
administration with CsA resulted in a 73% increase in edoxaban peak concentration and 72% increase in 315 
AUC.[62] Furthermore, the active circulating metabolite was observed to increase by greater than 7-fold 316 
for the both peak concentrations and AUC. In the population pharmacokinetic analysis of all VTE studies, 317 
no significant exposure-response for bleeding was observed in in patients on 30 mg daily, however the 318 
risk of recurrent VTE was modestly higher (1.77% vs. 1.57%) compared to patients on 60 mg.[63] The 319 
product label outlines  30 mg once daily dose of edoxaban for patients with creatinine clearances between 320 
15 to 50 mL/min, body weight < 60 kg, or those on certain P-gp inhibitors.[60]  321 
4.5. Apixaban 322 
Apixaban is indicated for the treatment and prevention of VTE and reducing the risk of stroke  in 323 
atrial fibrillation.[64] Absorption occurs primarily in the upper gastrointestinal tract with a reduction in its 324 
absorption witnessed in more distal sites of the intestines.[65] Alterations in gastric acidity is not 325 
anticipated to produce significant changes since apixaban has no ionizable groups across physiological pH. 326 
Apixaban has an absolute bioavailability of approximately 50% and demonstrates dose-proportional 327 
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increases in AUC for oral doses up to 10 mg. Approximately 87% of drug is bound to protein while the 328 
distribution volume is low at 21 liters. Metabolism is predominately through CYP3A4 with a quarter of its 329 
metabolites appearing in urine and feces. Less than a third of apixaban is eliminated through renal 330 
excretion whereas the remaining fraction occurs through biliary and intestinal secretion into the feces.  331 
Apixaban is a substrate for P-gp and BCRP with an estimated half-life of 12 hours. Using in-vitro 332 
permeability and transport assays with transfected cell monolayers, apixaban undergoes concentration 333 
and time-dependent transport via P-gp and BCRP with efflux ratios between 23-38 and 8-12, 334 
respectively.[66] In inhibition studies using Caco-2 bidirectional monolayers together with CsA, a non-335 
specific inhibitor of P-gp and BCRP, the observed inhibition of apixaban efflux was 64%.[51] The efflux of 336 
apixaban is inhibited by 13% in comparison to verapamil, a strong and specific inhibitor of P-gp. As a result, 337 
although P-gp has a role in apixaban intestinal efflux, BCRP-dependent transport may predominate. 338 
A concentration-dependent increase in anti-FXa activity is observed following single and multiple 339 
oral doses of apixaban. Intrinsic and extrinsic covariates that predicted apixaban total clearance are age, 340 
sex, race, renal function and co-administration of dual moderate and strong CYP3A4 and P-gp 341 
inhibitors.[67] Independent contributions from age, sex, race, and co-medications resulted in less than a 342 
25% increase in apixaban exposures. Those with mild, moderate and severe renal dysfunction were found 343 
to have 17%, 34%, and 56% higher exposures, respectively.  344 
Considering that close to one-third of the total systemic clearance of apixaban is due to renal 345 
elimination, decline in renal function is expected to largely affect the magnitude of exposure. Although 346 
intrinsic covariates such as age, sex, and race identified less than a quarter change in apixaban exposures, 347 
clinicians should be cognizant of additive effects when multiple factors are present. Declining renal 348 
function from CNI exposure may also be synergistic with previously mentioned factors and can potentially 349 
contribute to higher apixaban exposures. The PK of apixaban was evaluated in 12 healthy male volunteers 350 
together with CsA and tacrolimus. Following multiple-doses of CsA and tacrolimus, the AUC and Cmax of a  351 
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single 10 mg apixaban dose was observed to increase by 20% and 43% for CsA but decline by 22% and 352 
13% for tacrolimus when compared to apixaban alone, respectively.[68] The contrasting effects of 353 
cyclosporine and tacrolimus on apixaban exposure noted in the study were unexpected, and the 354 
mechanism unclear. Based on safety analyses, elevated apixaban exposure and peak concentrations alone 355 
after co-administration with CsA is not anticipated to pose any clinically relevant bleeding events. In the 356 
case of tacrolimus, a 22% reduction in exposure may not result in loss of efficacy as witnessed in subjects 357 
with body weights > 120 kg. With a 25% decline in apixaban exposures due to extreme body weight, a 358 
third as many patients experienced a stroke or thromboembolic compared to warfarin observed from 359 
pivotal trials in atrial fibrillation.[69] Additionally, although within the lower bounds of apixaban 360 
exposures, tacrolimus co-administration is not expected to confer loss of efficacy at the indicated 2.5 mg 361 
twice-daily dose for VTE prophylaxis.[67] Although each factor is independent, the synergism from body 362 
weight being greater than 120 kg and tacrolimus use should warrant further clinical monitoring as the 363 
combination of both may compromise efficacy. 364 
 365 
8. Conclusion  366 
VTE is common in solid organ transplant recipients. The decision to choose DOAC over warfarin in 367 
this subset of patients is largely limited by the perceived risk of DDIs leading to bleeding or thrombotic 368 
concerns provoked by CNI maintenance immunosuppression therapy. DOACs have much less dose-369 
response variability than warfarin, and accordingly do not require therapeutic monitoring, dose titration, 370 
or frequent dosage adjustments. This is an attractive option for transplant recipients requiring 371 
anticoagulation considering a large majority of individuals require lifelong chronic medications for 372 
immunosuppression and other comorbidities. Unfortunately, DOACs may be underutilized based on the 373 
DDI potential provoked by CNI use for maintenance immunosuppression. A visual is provided in figure 2 374 
which summarizes the available evidence relevant to the pharmacokinetic changes that best emulates 375 
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that of CsA and tacrolimus. In the absence of a dedicated DDI study between a particular DOAC and CNI, 376 
clinicians can extrapolate the information presented for an inhibitor that shares the same inhibitory 377 
pathway with caution. Rather, educating patients to monitor for signs of bleeding or thrombosis is 378 
encouraged at present.  379 
 380 
9. Expert Opinion  381 
For the transplant recipient, DOAC selection is individualized and based on factors that may 382 
attenuate higher or lower anticoagulant exposure while on a CNI. It is estimated that the 5-year risk of 383 
chronic kidney disease after non-renal transplant ranges between 7 to 21%.[70] Indeed renal function 384 
may decline overtime as a result of CNI exposure, age, and pre-existing comorbidities. Since a considerable 385 
fraction of DOACs are cleared by the kidneys, renal function is an important consideration when selecting 386 
an anticoagulant for the transplant recipient. Furthermore, an important consideration is the site of drug 387 
interaction. For example, interactions with dabigatran etexilate occur primarily at the absorption level 388 
where P-gp efflux in the intestines predominates. The active drug, dabigatran, is then renally cleared 389 
without further interaction with P-gp in elimination organs (e.g. biliary ducts) or drug metabolizing 390 
enzymes. In comparison, direct FXa inhibitors may have interactions occurring at the absorption and 391 
elimination phase. This may further enhance exposure and increase the probability of a bleeding event 392 
during which metabolism or excretion is inhibited (e.g. CsA). Together with declining renal function, 393 
bleeding risks may increase when both the absorption and elimination pathways are inhibited. Although 394 
one factor alone may not enhance the safety risk, presence of renal dysfunction, CNI, additional P-gp or 395 
CYP3A4 inhibitors (e.g. antifungals or antibiotics) or other covariates (e.g. extremes in body weight) may 396 
contribute to a higher likelihood of bleeding. In the case of apixaban co-administered with tacrolimus, the 397 
reduction in apixaban exposure and peak concentration does not warrant efficacy concern. However, the 398 
likelihood of any compromise to efficacy is currently unknown for individuals with > 120 kg in body weight 399 
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co-medicated with apixaban and tacrolimus. Interestingly, data from a large cohort of 91,330 Taiwanese 400 
patients found no significant risk of major bleeding in combined DOAC users with concurrent use of 401 
CsA.[71] Although the population of those using CsA together with DOACs was small at 0.62%, the risk of 402 
a major bleed was observed to be five-times greater in those taking apixaban compared to propensity-403 
score matched controls.  404 
Bleeding during CsA and rivaroxaban therapy have also been reported in small observational 405 
studies.[72,73] Although the number of patients included were small, both trough rivaroxaban 406 
concentration and anti-FXa activity were within the ranges considered therapeutic at their respective 407 
doses.[74] It should be noted that with each case, the reported creatinine clearances were far below the 408 
threshold value of 80 mL/min for which rivaroxaban is contraindicated in patients receiving dual P-gp and 409 
moderate CYP3A4 inhibitors. These results reflect several important implications for clinical practice 410 
where 1) dosage adjustments should be made to reflect renal function and CNI co-administration, 2) 411 
although the use of anti-FXa activity as a correlate to plasma drug levels is appropriate for FXa inhibitors, 412 
calibration specificity of anti-FXa activity for the FXa inhibitor (i.e. rivaroxaban, apixaban, or edoxaban) is 413 
critical to make an accurate determination and 3) lastly, the choice of tacrolimus for immunosuppression 414 
may be favorable compared to CsA. In a single-center retrospective cohort study in 37 thoracic transplant 415 
patients on concomitant DOAC and CNI therapy, bleeding rates were comparable to those without DDIs 416 
during DOAC therapy.[75] Tacrolimus was used in 73% of patients with 78% of the patients on rivaroxaban. 417 
The median creatinine clearance at the initiation of DOAC therapy was 59 mL/min. DOACs were used first-418 
line as anticoagulation therapy for VTE in this report. Lung transplant recipients received rivaroxaban as 419 
the preferred DOAC if their creatinine clearances were above 30 mL/min, whereas apixaban was selected 420 
for those with creatinine clearances less than 30 mL/min. Those with identified DDIs- including roughly a 421 
quarter of those on CsA- were found to not have any statistically significant incidences in bleeding 422 
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compared to those without identified DDIs. These observational studies, although limited in the sample 423 
size, may demonstrate the role of DOACs in transplant recipients requiring anticoagulation.  424 
Considering that most maintenance immunosuppressive regimens now contain tacrolimus, 425 
bleeding risks with DOACs may be less of a concern from DDIs. In the case of those requiring 426 
immunosuppression using CsA, which is a P-gp, BCRP, OATP and moderate CYP3A4 inhibitor, dabigatran 427 
etexilate may be appropriate based on its predominate P-gp transport in the gastrointestinal tract. This 428 
recommendation can be complicated considering that regulatory labeling for CsA recommend against use 429 
with dabigatran etexilate.[16,17] In addition, real-world limitations such as complex physiological 430 
changes, affordability, or insurance coverage may discourage the use of one DOAC over another.  431 
As thrombosis research continues, development of safer and effective anticoagulants may offer a 432 
solution to DDI concerns. As an example, darexaban, a FXa inhibitor in clinical development demonstrated 433 
no relevant interactions in the presence of strong dual P-gp and CYP3A4 inducers suggesting a low 434 
potential of clinically relevant DDIs.[74] Unfortunately, further development of the compound was 435 
discontinued. In addition, small molecules targeting factors XII and XI are in development and may provide 436 
a safer alternative to potential bleeding risks encountered with current DOACs.[75] Future research 437 
applying pharmacometric and pharmacoepidemiological methods using rich data sources like the 438 
electronic medical record would be most useful in determining the pharmacokinetic-pharmacodynamic 439 
interaction within this subgroup.    440 
Taken together, clinicians should consider the complex physiological changes that affect the 441 
absorption and elimination of drugs following transplantation to fully optimize anticoagulation therapy in 442 
recipients. Monitoring for renal function is essential in order to individualize anticoagulation therapy with 443 
DOACs. Monitoring of anti-FXa levels requires a drug specific assay, drug dosed to steady state, and a rigid 444 
attention to dose and draw time. There is no standardized dose adjustment based upon anti-FXa level and 445 
for these reasons the use of monitoring is discouraged. Dosage adjustments should follow the product 446 
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labeling with attention to renal function. Although limited, pharmacokinetic-pharmacodynamic and 447 
observational data suggest that the use of CNIs, specifically tacrolimus, together with DOACs is safe and 448 
effective.   449 
 Drug doses used for primary prophylaxis of VTE are less than those used for treatment of acute 450 
thrombosis or for secondary prophylaxis for a prior thrombotic event. The magnitude of any DDI will be 451 
accordingly less. Additional bleeding events attributable to prophylactic/low dose anticoagulation are low. 452 
For these reasons, patients with solid organ transplantation should have doses of thromboprophylactics 453 
guided by the general FDA approval label for all agents. In general, if there is concern for need of an 454 
invasive procedure or short term increased bleeding risk in an inpatient setting, the use of an injectable 455 
agent such as enoxaparin or unfractionated heparin is preferable to a DOAC without a readily available 456 
reversible agent. 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
 467 
 468 
 469 
 470 
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Table 1. Summary changes to DOAC pharmacokinetics measured as changes in peak concentrations (Cmax) and exposure (AUC).  686 
Drug 
In-vitro 
Transporter 
Affinity 
Perpetrator 
Victim / 
Perpetrator 
Regimen Studied 
Effect of P-gp 
and/or CYP3A4 
Inhibition 
Comments Reference 
Dabigatran 
Predominantly P-
gp dependent 
transport 
Verapamil  
Single-dosed DE 150 
mg 2 hours before + 
verapamil IR 120 mg 
BID  
Cmax: ↑18%                                                                                              
AUC: ↑12% 
Do not use together with P-gp 
inhibitor if creatinine clearance is < 50 
mL/min. Labeling for both 
cyclosporine formulations suggest 
avoiding co-administration with 
dabigatran. 
[16, 17, 51, 52, 
53]  Ritonavir 
Single-dosed DE 150 
mg 2 hours before + 
ritonavir 100 mg 
daily 
Cmax: ↓ 27%                                                                                           
AUC: ↓ 29% 
Ritonavir 
Single-dosed DE 150 
mg + ritonavir 100 
mg daily 
Cmax: ↑13%                                                                                              
AUC: ↑15% 
Rivaroxaban 
Equivalent P-gp 
& BCRP transport 
Fluconazole 
Single-dose 
rivaroxaban 20 mg+ 
fluconazole 400 mg 
daily for 5 days   
Cmax: ↑28%                                                                                              
AUC: ↑42% Do not use together with P-gp and 
strong CYP3A4 inhibitor if creatinine 
clearance < 80 mL/min. No dedicated 
CsA or Tacrolimus DDI conducted. 
Fluconazole is a BCRP inhibitor. 
Erythromycin is a P-gp and moderate 
CYP3A4 inhibitor. 
[51, 58]  
Erythromycin 
Single-dose 
rivaroxaban 10 mg 
+erythromycin 500 
mg TID for 4 days   
Cmax: ↑38%                                                                                              
AUC: ↑34% 
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Edoxaban 
Equivalent P-gp 
& BCRP transport 
Cyclosporine 
Single-dose 
edoxaban 60 mg + 
single-dose CsA 500 
mg   
Cmax: ↑ 74%                                                                                           
AUC: ↑ 73% 
Recommended dose of 30 mg once-
daily. Patients on CsA were excluded 
from pivotal VTE trial. CsA is an 
inhibitor of OATP1B1 uptake for M4 
metabolite. 
[51, 62]  
M4 (active 
metabolite) 
Unknown Cyclosporine 
Cmax: ↑ 8.7 fold                                                                                           
AUC: ↑ 6.9 fold 
Apixaban 
Preferential 
BCRP-dependent 
transport 
Cyclosporine 
Single-dose 
apixaban 10 mg + 
CsA  100 mg daily 
for 3 days  
Cmax: ↑43%                                                                                              
AUC: ↑20% 
No clinically meaningful impact on 
efficacy or safety with elevated 
exposure together with CsA; reduced 
expsoure together with tacrolimus.  
[51, 68]  
Tacrolimus 
Single-dose 
apixaban 10 mg + 
tacrolimus  5 mg 
daily for 3 days 
Cmax: ↓ 13%                                                                                           
AUC: ↓ 22% 
AUC: Area under the plasma-concentration time curve extrapolated to infinity, BCRP: Breast Cancer Resistance Protein, BID: Twice-daily, Cmax: Peak 687 
plasma concentration, CsA: Cyclosporine, DDI: Drug-drug interaction, DE: Dabigatran etexilate, IR: Immediate-release, OATP: Organic anion 688 
transporting polypeptide1B1, P-gp: Permeability glycoprotein, TID: Three times-daily 689 
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Figure 1. Physiological changes following solid organ transplantation that impact the pharmacokinetics (absorption, distribution, metabolism, and 700 
excretion) of drugs.   701 
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 718 
The illustration is a derivative of “Arterial circulation”, “Arrow”, “Capsule”, and “Complete digestive apparatus” by Servier Medical Art 719 
(https://smart.servier.com/) under the Creative Commons License (CC BY 3.0).  720 
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Figure 2: Effect of cyclosporine, tacrolimus, or similar perpetrator drugs on the pharmacokinetics of DOACs. 721 
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 738 
Results from dedicated drug-drug interaction studies in healthy-volunteers for dabigatran, rivaroxaban, edoxaban (and M4 metabolite), and 739 
apixaban. Reference values for the individual direct oral anticoagulant are for the AUC and Cmax parameters in the absence of the co-administered 740 
drugs. Cmax, peak concentrations. AUC, area under the plasma concentration-time curve from time zero extrapolated to infinity. CI, confidence 741 
interval.  742 
